CLS vs. KNSA
CLS (Celestica Inc.) and KNSA (Kiniksa Pharmaceuticals, Ltd.) are both stocks. CLS operates in Electronic Components (Technology), while KNSA operates in Biotechnology (Healthcare). Over the past 5 years, CLS returned 116.85%/yr vs 29.69%/yr for KNSA. At a 0.15 correlation, their price movements are largely independent.
Performance
CLS vs. KNSA - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CLS achieves a 26.03% return, which is significantly lower than KNSA's 33.60% return.
CLS
- 1D
- -2.06%
- 1M
- 1.41%
- YTD
- 26.03%
- 6M
- 27.46%
- 1Y
- 175.49%
- 3Y*
- 196.86%
- 5Y*
- 116.85%
- 10Y*
- 43.04%
KNSA
- 1D
- 1.66%
- 1M
- 3.51%
- YTD
- 33.60%
- 6M
- 27.60%
- 1Y
- 93.78%
- 3Y*
- 52.43%
- 5Y*
- 29.69%
- 10Y*
- —
CLS vs. KNSA - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
CLS Celestica Inc. | 26.03% | 220.27% | 215.23% | 159.80% | 1.26% | 37.92% | -2.42% | -5.70% | -26.61% |
KNSA Kiniksa Pharmaceuticals, Ltd. | 33.60% | 108.54% | 12.77% | 17.09% | 27.27% | -33.39% | 59.76% | -60.63% | 14.89% |
Correlation
The correlation between CLS and KNSA is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.05 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (All Time) Calculated using the full available price history since May 24, 2018 | 0.15 |
The correlation between CLS and KNSA shifts across timeframes, from 0.05 (1 year) to 0.17 (5 years), reflecting how their relationship changes across market environments.
Fundamentals
CLS:
$43.10B
KNSA:
$4.54B
CLS:
$8.28
KNSA:
$0.92
CLS:
44.97
KNSA:
59.85
CLS:
0.60
KNSA:
0.58
CLS:
3.13
KNSA:
5.80
CLS:
20.54
KNSA:
7.50
CLS:
$13.81B
KNSA:
$754.05M
CLS:
$1.60B
KNSA:
$294.06M
CLS:
$1.32B
KNSA:
$101.06M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CLS vs. KNSA — Risk / Return Rank
CLS
KNSA
CLS vs. KNSA - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Celestica Inc. (CLS) and Kiniksa Pharmaceuticals, Ltd. (KNSA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| CLS | KNSA | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.13 | ||
| Sortino ratioReturn per unit of downside risk | -0.71 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.41 | -0.07 |
| Calmar ratioReturn relative to maximum drawdown | 5.97 | 4.63 | +1.34 |
| Martin ratioReturn relative to average drawdown | 14.26 | 16.35 | -2.09 |
Loading charts...
Drawdowns
CLS vs. KNSA - Drawdown Comparison
The maximum CLS drawdown since its inception was -96.93%, which is greater than KNSA's maximum drawdown of -83.06%. Use the drawdown chart below to compare losses from any high point for CLS and KNSA.
Loading charts...
Drawdown Indicators
| CLS | KNSA | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -96.93% | -83.06% | -13.87% |
Max Drawdown (1Y)Largest decline over 1 year | -29.24% | -21.12% | -8.12% |
Max Drawdown (3Y)Largest decline over 3 years | -53.96% | -34.14% | -19.82% |
Max Drawdown (5Y)Largest decline over 5 years | -53.96% | -53.17% | -0.79% |
Max Drawdown (10Y)Largest decline over 10 years | -80.60% | — | — |
Current DrawdownCurrent decline from peak | -21.14% | -7.35% | -13.79% |
Average DrawdownAverage peak-to-trough decline | -73.28% | -40.60% | -32.68% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.21% | 5.97% | +6.24% |
Volatility
CLS vs. KNSA - Volatility Comparison
Celestica Inc. (CLS) has a higher volatility of 27.00% compared to Kiniksa Pharmaceuticals, Ltd. (KNSA) at 10.40%. This indicates that CLS's price experiences larger fluctuations and is considered to be riskier than KNSA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CLS | KNSA | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 27.00% | 10.40% | +16.60% |
Volatility (6M)Calculated over the trailing 6-month period | 53.80% | 34.02% | +19.78% |
Volatility (1Y)Calculated over the trailing 1-year period | 72.73% | 43.03% | +29.70% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 57.74% | 53.48% | +4.26% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 50.01% | 63.93% | -13.92% |
Dividends
CLS vs. KNSA - Dividend Comparison
Neither CLS nor KNSA has paid dividends to shareholders.
Financials
CLS vs. KNSA - Financials Comparison
This section allows you to compare key financial metrics between Celestica Inc. and Kiniksa Pharmaceuticals, Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
CLS vs. KNSA - Profitability Comparison
CLS - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a gross profit of 437.20M and revenue of 4.05B. Therefore, the gross margin over that period was 10.8%.
KNSA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.
CLS - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported an operating income of 272.10M and revenue of 4.05B, resulting in an operating margin of 6.7%.
KNSA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.
CLS - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Celestica Inc. reported a net income of 212.30M and revenue of 4.05B, resulting in a net margin of 5.3%.
KNSA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.
Frequently Asked Questions
CLS and KNSA have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CLS has higher volatility (27.00%) compared to KNSA (10.40%). In terms of maximum drawdown, CLS dropped -96.93% vs KNSA's -83.06%.
CLS currently has the higher Sharpe Ratio (2.40 vs 2.27), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CLS and KNSA
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer